Cargando…

Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma

The foundation of precision immunotherapy in oncology is rooted in computational biology and patient-derived sample sequencing to enrich for and target immunogenic epitopes. Discovery of these tumor-specific epitopes through tumor sequencing has revolutionized patient outcomes in many types of cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Lookian, Pashayar P., Zhao, David, Medina, Rogelio, Wang, Herui, Zenka, Jan, Gilbert, Mark R., Pacak, Karel, Zhuang, Zhengping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037428/
https://www.ncbi.nlm.nih.gov/pubmed/33810617
http://dx.doi.org/10.3390/ijms22073455
_version_ 1783677141203812352
author Lookian, Pashayar P.
Zhao, David
Medina, Rogelio
Wang, Herui
Zenka, Jan
Gilbert, Mark R.
Pacak, Karel
Zhuang, Zhengping
author_facet Lookian, Pashayar P.
Zhao, David
Medina, Rogelio
Wang, Herui
Zenka, Jan
Gilbert, Mark R.
Pacak, Karel
Zhuang, Zhengping
author_sort Lookian, Pashayar P.
collection PubMed
description The foundation of precision immunotherapy in oncology is rooted in computational biology and patient-derived sample sequencing to enrich for and target immunogenic epitopes. Discovery of these tumor-specific epitopes through tumor sequencing has revolutionized patient outcomes in many types of cancers that were previously untreatable. However, these therapeutic successes are far from universal, especially with cancers that carry high intratumoral heterogeneity such as glioblastoma (GBM). Herein, we present the technical aspects of Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) vaccine immunotherapy, an investigational therapeutic that potentially circumvents the need for in silico tumor-neoantigen enrichment. We then review the most promising GBM vaccination strategies to contextualize the MBTA vaccine. By reviewing current evidence using translational tumor models supporting MBTA vaccination, we evaluate the underlying principles that validate its clinical applicability. Finally, we showcase the translational potential of MBTA vaccination as a potential immunotherapy in GBM, along with established surgical and immunologic cancer treatment paradigms.
format Online
Article
Text
id pubmed-8037428
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80374282021-04-12 Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma Lookian, Pashayar P. Zhao, David Medina, Rogelio Wang, Herui Zenka, Jan Gilbert, Mark R. Pacak, Karel Zhuang, Zhengping Int J Mol Sci Review The foundation of precision immunotherapy in oncology is rooted in computational biology and patient-derived sample sequencing to enrich for and target immunogenic epitopes. Discovery of these tumor-specific epitopes through tumor sequencing has revolutionized patient outcomes in many types of cancers that were previously untreatable. However, these therapeutic successes are far from universal, especially with cancers that carry high intratumoral heterogeneity such as glioblastoma (GBM). Herein, we present the technical aspects of Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) vaccine immunotherapy, an investigational therapeutic that potentially circumvents the need for in silico tumor-neoantigen enrichment. We then review the most promising GBM vaccination strategies to contextualize the MBTA vaccine. By reviewing current evidence using translational tumor models supporting MBTA vaccination, we evaluate the underlying principles that validate its clinical applicability. Finally, we showcase the translational potential of MBTA vaccination as a potential immunotherapy in GBM, along with established surgical and immunologic cancer treatment paradigms. MDPI 2021-03-26 /pmc/articles/PMC8037428/ /pubmed/33810617 http://dx.doi.org/10.3390/ijms22073455 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Review
Lookian, Pashayar P.
Zhao, David
Medina, Rogelio
Wang, Herui
Zenka, Jan
Gilbert, Mark R.
Pacak, Karel
Zhuang, Zhengping
Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma
title Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma
title_full Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma
title_fullStr Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma
title_full_unstemmed Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma
title_short Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma
title_sort mannan-bam, tlr ligands, anti-cd40 antibody (mbta) vaccine immunotherapy: a review of current evidence and applications in glioblastoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037428/
https://www.ncbi.nlm.nih.gov/pubmed/33810617
http://dx.doi.org/10.3390/ijms22073455
work_keys_str_mv AT lookianpashayarp mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma
AT zhaodavid mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma
AT medinarogelio mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma
AT wangherui mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma
AT zenkajan mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma
AT gilbertmarkr mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma
AT pacakkarel mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma
AT zhuangzhengping mannanbamtlrligandsanticd40antibodymbtavaccineimmunotherapyareviewofcurrentevidenceandapplicationsinglioblastoma